OverviewSuggest Edit

Bolt Biotherapeutics is a biotechnology company developing immunotherapeutics for multiple types of cancer. Its Immune-stimulating Antibody Conjugates (ISAC) eliminate tumors following systemic administration in preclinical studies and results in the development of immunological memory. The company also develops Myeloid Modulator Platform that reawakens myeloid cells to attack tumor cells.

TypePublic
Founded2015
HQRedwood City, CA, US
Websiteboltbio.com

Latest Updates

Employees (est.) (Sept 2020)63
Job Openings24
Revenue (FY, 2019)$215 K
Share Price (May 2022)$1.4(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Bolt Biotherapeutics

Randy Schatzman

Randy Schatzman

Chief Executive Officer
Grant Yonehiro

Grant Yonehiro

Chief Business Officer
Priti Hegde

Priti Hegde

Chief Scientific Officer
Edith Perez

Edith Perez

Chief Medical Officer
William P Quinn

William P Quinn

Chief Financial Officer
Roy S. Herbst

Roy S. Herbst

Chief of Medical Oncology, Director for Translational Research
Show more

Bolt Biotherapeutics Office Locations

Bolt Biotherapeutics has an office in Redwood City
Redwood City, CA, US (HQ)
900 Chesapeake Dr
Show all (1)

Bolt Biotherapeutics Financials and Metrics

Bolt Biotherapeutics Revenue

Bolt Biotherapeutics's revenue was reported to be $215 k in FY, 2019
USD

Net income (Q1, 2021)

(24.5m)

EBIT (Q1, 2021)

(18.4m)

Market capitalization (6-May-2022)

52.6m

Closing stock price (6-May-2022)

1.4

Cash (31-Mar-2021)

95.5m

EV

(32.2m)
Bolt Biotherapeutics's current market capitalization is $52.6 m.
Annual
USDFY, 2018FY, 2019

Revenue

215.0k

General and administrative expense

2.2m5.2m

R&D expense

9.4m26.0m

Operating expense total

11.6m31.2m
Quarterly
USDQ1, 2021

General and administrative expense

4.3m

R&D expense

14.1m

Operating expense total

18.4m

EBIT

(18.4m)
Annual
USDFY, 2018FY, 2019

Cash

13.6m34.8m

Prepaid Expenses

466.0k1.1m

Current Assets

14.1m35.9m

PP&E

1.4m1.4m
Quarterly
USDQ3, 2020Q1, 2021

Cash

17.8m95.5m

Prepaid Expenses

1.9m4.5m

Current Assets

39.7m271.2m

PP&E

4.2m3.9m
Annual
USDFY, 2018FY, 2019

Net Income

(11.6m)(30.5m)

Depreciation and Amortization

302.0k335.0k

Accounts Payable

1.3m2.1m

Cash From Operating Activities

(9.9m)(26.3m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(21.1m)(29.7m)(24.5m)

Depreciation and Amortization

239.0k390.0k272.0k

Accounts Payable

365.0k(221.0k)(88.0k)

Cash From Operating Activities

(20.1m)(34.4m)(16.6m)
USDFY, 2018

Financial Leverage

-1 x
Show all financial metrics

Bolt Biotherapeutics Operating Metrics

FY, 2020

Co-Owned Patent Applications (Foreign)

50

Co-Owned Patent Applications (US)

21

Patents (US)

1
Show all operating metrics

Bolt Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Bolt Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Bolt Biotherapeutics Online and Social Media Presence

Embed Graph

Bolt Biotherapeutics News and Updates

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste…

Bolt Biotherapeutics to Participate in Upcoming February Conferences

REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, tod…

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune system…

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, tod…

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune system…
Show more

Bolt Biotherapeutics Frequently Asked Questions

  • When was Bolt Biotherapeutics founded?

    Bolt Biotherapeutics was founded in 2015.

  • Who are Bolt Biotherapeutics key executives?

    Bolt Biotherapeutics's key executives are Randy Schatzman, Grant Yonehiro and Priti Hegde.

  • How many employees does Bolt Biotherapeutics have?

    Bolt Biotherapeutics has 63 employees.

  • What is Bolt Biotherapeutics revenue?

    Latest Bolt Biotherapeutics annual revenue is $215 k.

  • What is Bolt Biotherapeutics revenue per employee?

    Latest Bolt Biotherapeutics revenue per employee is $3.4 k.

  • Who are Bolt Biotherapeutics competitors?

    Competitors of Bolt Biotherapeutics include Forbius, OncoQR ML and Nkarta Therapeutics.

  • Where is Bolt Biotherapeutics headquarters?

    Bolt Biotherapeutics headquarters is located at 900 Chesapeake Dr, Redwood City.

  • Where are Bolt Biotherapeutics offices?

    Bolt Biotherapeutics has an office in Redwood City.

  • How many offices does Bolt Biotherapeutics have?

    Bolt Biotherapeutics has 1 office.